

# MULTIPLE SCLEROSIS (MS) : DISEASE OVERVIEW

## WHAT IS MULTIPLE SCLEROSIS?

- Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (the central nervous system).<sup>1</sup> Relapsing forms of multiple sclerosis (RMS) includes the following forms: clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS).<sup>2</sup> Relapsing-remitting MS is the most common initial form of MS at diagnosis, and is defined as MS in which patients have relapses of MS and periods of stability in between relapses.<sup>3</sup>



## PREVALENCE OF MS



## DIAGNOSIS OF MS

**~25,000**  
new people in the US are diagnosed each year<sup>5</sup>



Most people are diagnosed between the ages of

**20** and **50**

although children and older adults may develop it<sup>6</sup>



**In the US** **36 years** is the average age of an MS diagnosis<sup>5</sup>

**74%** of people with MS are **women**<sup>5</sup>

**~85%** of people with MS are initially diagnosed with RRMS<sup>5</sup>



## MS MARKET DYNAMICS (US)

**~350,000** patients are on a disease modifying therapy<sup>7</sup>

**~80,000** patients start their first or switch to a new MS therapy each year<sup>7</sup>

As of Q3 2022

**~50%** of patients starting their first or starting a new MS therapy, use a anti-CD20<sup>8</sup>

1. <https://www.nationalmssociety.org/What-is-MS>.  
2. <https://www.nationalmssociety.org/What-is-MS/Types-of-MS>.  
3. <https://my.clevelandclinic.org/health/diseases/14905-ms-relapsing-remitting-multiple-sclerosis-rrms>.  
4. <https://www.nationalmssociety.org/About-the-Society/News/Landmark-Study-Estimates-Nearly%2%A01-Million-in-the-U>  
<https://seer.cancer.gov/statfacts/html/common.html>. Accessed January 19, 2021.  
5. <https://www.atlasofms.org/map/global/epidemiology/number-of-people-with-ms>.  
6. <https://www.nationalmssociety.org/What-is-MS/Who-Gets-MS>.  
7. Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology 2019;92:e1029-e1040 & From September 2021 to September 2022; Komodo Claims.  
8. Roche and Novartis Q3'22 Earnings Call Statements.



TG Therapeutics